Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Revenues up 5% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

BMS Revenues up 5% in the Quarter

Eliquis and Opdivo, and new product portfolio drive growth, partially offset by recent loss of exclusivity for Revlimid and Abraxane.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Financial Report: Bristol-Myers Squibb
1Q Revenues: $11.6 billion (+5%)
1Q Earnings: $2.0 billion (+4%)
Comments: Growth in the quarter was primarily driven by Eliquis and Opdivo, and new product portfolio (primarily cell therapy products and Reblozyl), partially offset by recent loss of exclusivity for Revlimid and Abraxane, and foreign exchange impacts.
 
Eliquis revenues grew 11% to $3.2 billion. Opdivo revenues increased 12% to $1.9 billion driven by higher demand across multiple indications including the Opdivo+Yervoy  based combinations for non-small cell lung cancer (NSCLC), Opdivo+Cabometyx combination for kidney cancer, and Opdivo-based therapies for various gastric and esophageal cancers. 
 
New product portfolio revenues grew to $350 million compared to $161 million in 1Q21, driven by higher demand primarily relating to Abecma, Breyanzi and Reblozyl. Revlimid revenues declined by 5% to $2.8 billion. Abraxane revenues declined 32% to $214 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters